...
search icon
kura-img

Kura Oncology Inc, Common Stock

KURA

NSQ

$5.64

-$0.6

(-9.62%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$540.23M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.50
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.41 L
$23.48 H
$5.64

About Kura Oncology Inc, Common Stock

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameKURASectorS&P500
1-Week Return-6.31%-1.91%-1.87%
1-Month Return-11.46%-3.82%8.93%
3-Month Return-28.43%-11.56%-2.39%
6-Month Return-48.54%-10.21%-2.41%
1-Year Return-73.68%-9.91%10.88%
3-Year Return-55.76%-0.28%46.93%
5-Year Return-65.53%31.29%94.89%
10-Year Return-62.4%75.9%177.5%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue----53.88M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue194.00K558.00K759.00K849.00K848.00K[{"date":"2020-12-31","value":22.85,"profit":true},{"date":"2021-12-31","value":65.72,"profit":true},{"date":"2022-12-31","value":89.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.88,"profit":true}]
Gross Profit(194.00K)(558.00K)(759.00K)(849.00K)53.03M[{"date":"2020-12-31","value":-0.37,"profit":false},{"date":"2021-12-31","value":-1.05,"profit":false},{"date":"2022-12-31","value":-1.43,"profit":false},{"date":"2023-12-31","value":-1.6,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin----98.43%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses91.90M131.26M139.87M165.80M247.08M[{"date":"2020-12-31","value":37.19,"profit":true},{"date":"2021-12-31","value":53.12,"profit":true},{"date":"2022-12-31","value":56.61,"profit":true},{"date":"2023-12-31","value":67.11,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(92.09M)(131.82M)(140.62M)(165.80M)(193.19M)[{"date":"2020-12-31","value":-9209300000,"profit":false},{"date":"2021-12-31","value":-13181600000,"profit":false},{"date":"2022-12-31","value":-14062400000,"profit":false},{"date":"2023-12-31","value":-16580400000,"profit":false},{"date":"2024-12-31","value":-19319500000,"profit":false}]
Total Non-Operating Income/Expense4.50M1.58M8.05M24.41M42.46M[{"date":"2020-12-31","value":10.59,"profit":true},{"date":"2021-12-31","value":3.73,"profit":true},{"date":"2022-12-31","value":18.96,"profit":true},{"date":"2023-12-31","value":57.49,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(89.63M)(130.47M)(135.84M)(152.63M)(171.97M)[{"date":"2020-12-31","value":-8962500000,"profit":false},{"date":"2021-12-31","value":-13046600000,"profit":false},{"date":"2022-12-31","value":-13584000000,"profit":false},{"date":"2023-12-31","value":-15263100000,"profit":false},{"date":"2024-12-31","value":-17196500000,"profit":false}]
Income Taxes(194.00K)(558.00K)229.00K-2.02M[{"date":"2020-12-31","value":-9.61,"profit":false},{"date":"2021-12-31","value":-27.65,"profit":false},{"date":"2022-12-31","value":11.35,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(89.43M)(129.91M)(136.07M)-(173.98M)[{"date":"2020-12-31","value":-8943100000,"profit":false},{"date":"2021-12-31","value":-12990800000,"profit":false},{"date":"2022-12-31","value":-13606900000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-17398300000,"profit":false}]
Income From Continuous Operations(89.63M)(130.47M)(135.84M)(142.96M)(173.98M)[{"date":"2020-12-31","value":-8962500000,"profit":false},{"date":"2021-12-31","value":-13046600000,"profit":false},{"date":"2022-12-31","value":-13584000000,"profit":false},{"date":"2023-12-31","value":-14295900000,"profit":false},{"date":"2024-12-31","value":-17398300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(89.43M)(129.91M)(136.07M)(152.63M)(173.98M)[{"date":"2020-12-31","value":-8943100000,"profit":false},{"date":"2021-12-31","value":-12990800000,"profit":false},{"date":"2022-12-31","value":-13606900000,"profit":false},{"date":"2023-12-31","value":-15263100000,"profit":false},{"date":"2024-12-31","value":-17398300000,"profit":false}]
EPS (Diluted)(1.69)(1.96)(2.03)(2.08)(2.03)[{"date":"2020-12-31","value":-169,"profit":false},{"date":"2021-12-31","value":-196,"profit":false},{"date":"2022-12-31","value":-203,"profit":false},{"date":"2023-12-31","value":-208,"profit":false},{"date":"2024-12-31","value":-203,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

KURA
Cash Ratio 7.33
Current Ratio 8.07

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KURA
ROA (LTM) -19.60%
ROE (LTM) -41.84%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KURA
Debt Ratio Lower is generally better. Negative is bad. 0.51
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.49

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KURA
Trailing PE NM
Forward PE NM
P/S (TTM) 7.18
P/B 1.34
Price/FCF NM
EV/R 3.00
EV/Ebitda NM
PEG NM

FAQs

What is Kura Oncology Inc share price today?

Kura Oncology Inc (KURA) share price today is $5.64

Can Indians buy Kura Oncology Inc shares?

Yes, Indians can buy shares of Kura Oncology Inc (KURA) on Vested. To buy Kura Oncology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KURA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kura Oncology Inc be purchased?

Yes, you can purchase fractional shares of Kura Oncology Inc (KURA) via the Vested app. You can start investing in Kura Oncology Inc (KURA) with a minimum investment of $1.

How to invest in Kura Oncology Inc shares from India?

You can invest in shares of Kura Oncology Inc (KURA) via Vested in three simple steps:

  • Click on Sign Up or Invest in KURA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kura Oncology Inc shares
What is Kura Oncology Inc 52-week high and low stock price?

The 52-week high price of Kura Oncology Inc (KURA) is $23.48. The 52-week low price of Kura Oncology Inc (KURA) is $5.41.

What is Kura Oncology Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kura Oncology Inc (KURA) is 1.34

What is the Market Cap of Kura Oncology Inc?

The market capitalization of Kura Oncology Inc (KURA) is $540.23M

What is Kura Oncology Inc’s stock symbol?

The stock symbol (or ticker) of Kura Oncology Inc is KURA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top